Liposomes and nanotechnology in drug development: focus on ocular targets

Poor drug delivery to lesions in patients’ eyes is a major obstacle to the treatment of ocular diseases. The accessibility of these areas to drugs is highly restricted by the presence of barriers, including the corneal barrier, aqueous barrier, and the inner and outer blood–retinal barriers. In particular, the posterior segment is difficult to reach for drugs because of its structural peculiarities. This review discusses various barriers to drug delivery and provides comprehensive information for designing nanoparticle-mediated drug delivery systems for the treatment of ocular diseases. Nanoparticles can be designed to improve penetration, controlled release, and drug targeting. As highlighted in this review, the therapeutic efficacy of drugs in ocular diseases has been reported to be enhanced by the use of nanoparticles such as liposomes, micro/nanospheres, microemulsions, and dendrimers. Our recent data show that intravitreal injection of targeted liposomes encapsulating an angiogenesis inhibitor caused significantly greater suppression of choroidal neovascularization than did the injection of free drug. Recent progress in ocular drug delivery systems research has provided new insights into drug development, and the use of nanoparticles for drug delivery is thus a promising approach for advanced therapy of ocular diseases.

• Publication year

  2012

• Venue

  International Journal of Nanomedicine

• Publication date

  2012-09-14

• Fields of study

  Biology, Medicine, Materials Science

• Identifiers
  DOI 10.2147/IJN.S30725PMID 23439842PMCID 3576887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

  2012cited by this paper
• Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.

  2012cited by this paper
• Nanomaterials for ocular drug delivery.

  2012cited by this paper
• Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

  2011cited by this paper
• DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS

  2011cited by this paper
• Recent advances in intraocular drug delivery systems.

  2011cited by this paper
• Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.

  2011influential reference
• Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.

  2011cited by this paper
• Oligomannose‐coated liposomes efficiently induce human T‐cell leukemia virus‐1‐specific cytotoxic T lymphocytes without adjuvant

  2011cited by this paper
• New Strategy of Adult T-cell Leukemia Treatment Targeted for Anti-tumor Immunity and a Longevity Gene-encoded Protein

  2011cited by this paper
• Target epitopes of HTLV‐1 recognized by class I MHC‐restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders

  2011cited by this paper
• Drug delivery to the posterior segment of the eye.

  2011cited by this paper
• Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.

  2011cited by this paper
• Drug delivery to the posterior segment of the eye.

  2010cited by this paper
• Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

  2010cited by this paper
• Anti-allergic potential of oligomannose-coated liposome-entrapped Cry j 1 as immunotherapy for Japanese cedar pollinosis in mice.

  2010cited by this paper
• Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.

  2010cited by this paper
• Molecular approach to human leukemia: Isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in Adult T-cell Leukemia

  2010cited by this paper
• Ocular Drug Delivery

  2010cited by this paper
• Targeted delivery of oligomannose‐coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer

  2010cited by this paper
• Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.

  2010cited by this paper
• Immunization with Oligomannose-Coated Liposome-Entrapped Dense Granule Protein 7 Protects Dams and Offspring from Neospora caninum Infection in Mice

  2009cited by this paper
• PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients

  2009cited by this paper
• Recent Perspectives in Ocular Drug Delivery

  2009cited by this paper
• Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization

  2009cited by this paper
• PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION

  2009cited by this paper
• Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles.

  2009cited by this paper
• Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.

  2009cited by this paper
• Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.

  2009cited by this paper
• Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

  2009cited by this paper
• Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.

  2009cited by this paper
• Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.

  2009cited by this paper
• INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS

  2009cited by this paper
• Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.

  2008cited by this paper
• Carbohydrate‐Mediated Targeting of Antigen to Dendritic Cells Leads to Enhanced Presentation of Antigen to T Cells

  2008cited by this paper
• Ocular novel drug delivery: impacts of membranes and barriers

  2008cited by this paper
• Dendrimers as drug carriers: applications in different routes of drug administration.

  2008cited by this paper
• Oligomannose-coated liposomes activate ERK via Src kinases and PI3K/Akt in J774A.1 cells.

  2008cited by this paper
• Dendritic cell based personalized immunotherapy based on cancer antigen research.

  2008cited by this paper
• HTLV-1 infection: role of CTL efficiency

  2008cited by this paper
• Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.

  2008cited by this paper
• Coencapsulation of CpG Oligodeoxynucleotides with Recombinant Leishmania major Stress-Inducible Protein 1 in Liposome Enhances Immune Response and Protection against Leishmaniasis in Immunized BALB/c Mice

  2008cited by this paper
• Microemulsions as potential drug delivery systems: a review.

  2008cited by this paper
• Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.

  2008cited by this paper
• VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

  2007cited by this paper
• Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues.

  2007cited by this paper
• A simple but effective cancer vaccine consisting of an antigen and a cationic lipid

  2007cited by this paper
• Intraperitoneal immunization with oligomannose‐coated liposome‐entrapped soluble leishmanial antigen induces antigen‐specific T‐helper type immune response in BALB/c mice through uptake by peritoneal macrophages

  2007cited by this paper
• Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines.

  2007cited by this paper
• Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging.

  2007cited by this paper
• Leukaemogenic mechanism of human T‐cell leukaemia virus type I

  2007cited by this paper
• Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.

  2007cited by this paper
• A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle.

  2006cited by this paper
• Myeloid C-type lectins in innate immunity

  2006cited by this paper
• Dendritic Cells That Endocytosed Antigen-Containing IgG-Liposomes Elicit Effective Antitumor Immunity

  2006cited by this paper
• Reduced Frequency, Diversity, and Function of Human T Cell Leukemia Virus Type 1-Specific CD8+ T Cell in Adult T Cell Leukemia Patients1

  2006cited by this paper
• Virus-like particles: Passport to immune recognition

  2006cited by this paper
• Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer

  2005cited by this paper
• Ligand-targeted liposomes for cancer treatment.

  2005cited by this paper
• Pathogen recognition with Toll-like receptors.

  2005cited by this paper
• Natural history of adult T-cell leukemia/lymphoma and approaches to therapy

  2005cited by this paper
• Graft-versus-Tax Response in Adult T-Cell Leukemia Patients after Hematopoietic Stem Cell Transplantation

  2004cited by this paper
• Divergent roles for C-type lectins expressed by cells of the innate immune system.

  2004cited by this paper
• In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits.

  2004cited by this paper
• New vehicle based on a microemulsion for topical ocular administration of dexamethasone

  2004cited by this paper
• Liposome-bound cyclosporine: Retinal toxicity after intravitreal injection

  2004cited by this paper
• Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes

  2004cited by this paper
• Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide.

  2004cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Drug delivery systems for vitreoretinal diseases.

  2004cited by this paper
• Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.

  2003cited by this paper
• Nanotech approaches to drug delivery and imaging.

  2003cited by this paper
• Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.

  2003influential reference
• Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells.

  2003cited by this paper
• Microemulsions as ocular drug delivery systems: recent developments and future challenges.

  2002cited by this paper
• Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor

  2002cited by this paper
• Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles1

  2002cited by this paper
• Intravitreal delivery of oligonucleotides by sterically stabilized liposomes.

  2002cited by this paper
• Anti-neovascular therapy using novel peptides homing to angiogenic vessels

  2002cited by this paper
• Innate immune recognition.

  2002cited by this paper
• Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.

  2001cited by this paper
• A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303

  2001cited by this paper
• Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses

  2001cited by this paper
• Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes

  2001cited by this paper
• Intravitreal Pharmacokinetics of Plain and Liposome-Entrapped Fluconazole in Rabbit Eyes

  2000cited by this paper
• Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery.

  2000cited by this paper
• Effect of Particle Size of Polymeric Nanospheres on Intravitreal Kinetics

  2000cited by this paper
• Prevention of Adult T-Cell Leukemia-Like Lymphoproliferative Disease in Rats by Adoptively Transferred T Cells from a Donor Immunized with Human T-Cell Leukemia Virus Type 1 Tax-Coding DNA Vaccine

  2000cited by this paper
• Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.

  2000cited by this paper
• Anticancer therapy using glucuronate modified long-circulating liposomes.

  1999cited by this paper
• Suture loop to aid in ganciclovir implant removal.

  1999cited by this paper
• Ocular neovascularization: an epidemiologic review.

  1998cited by this paper
• Liposome oligomannose‐coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes

  1998cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.

  1997cited by this paper
• Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant

  1997cited by this paper
• In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes

  1997cited by this paper
• Expression of vascular endothelial growth factor in experimental choroidal neovascularization

  1997cited by this paper
• Vascular endothelial growth factor expression in choroidal neovascularization in rats

  1997cited by this paper
• Mannose-binding lectin: the pluripotent molecule of the innate immune system.

  1996cited by this paper

• Therapeutic Potential of Tocopherol and Tocotrienol in Glaucoma Management

  2025cites this paper
• Exploring copper metabolism and cuproptosis, and their implications in ocular diseases.

  2025cites this paper
• Targeted Delivery Strategies for Hydrophilic Phytochemicals

  2025cites this paper
• Nanotechnological Advancements and Contribution to Healthcare and Medication Industries

  2025cites this paper
• Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications

  2025cites this paper
• Composite nano-in-micro drug delivery system for treatment of glaucoma: design strategies and research advances

  2025cites this paper
• Spatiotemporally engineered bilayer microneedles for biphasic drug delivery in corneal neovascularization therapy

  2025cites this paper
• Localization of fluorescent gold nanoparticles throughout the eye after topical administration

  2025cites this paper
• Biophysics of ophthalmic medications during spaceflight: Principles of ocular fluid dynamics and pharmacokinetics in microgravity.

  2024cites this paper
• Advances in Ophthalmic Therapeutic Delivery: A Comprehensive Overview of Present and Future Directions.

  2024cites this paper
• Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis

  2024cites this paper
• Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies

  2024cites this paper
• Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic.

  2024cites this paper
• Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease

  2024cites this paper
• Nano revolution: Exploring the frontiers of nanomaterials in science, technology, and society

  2024cites this paper
• Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens

  2024cites this paper
• Tailoring surface properties of liposomes for dexamethasone intraocular administration.

  2023cites this paper
• Nano-based eye drop: topical and noninvasive therapy for ocular diseases.

  2023cites this paper
• In vitro inhibition of rotavirus multiplication by copper oxide nanoparticles.

  2023cites this paper
• Unlocking the Potential of Bilosomes and Modified Bilosomes: a Comprehensive Journey into Advanced Drug Delivery Trends

  2023cites this paper
• Pharmaceutical and Pharmacokinetic Aspects of Nanoformulation Based Drug Delivery Systems for Anti-cancer Drugs.

  2023cites this paper
• Viscoelasticity of Liposomal Dispersions

  2023cites this paper
• Innovative Strategies for Drug Delivery to the Ocular Posterior Segment

  2023cites this paper
• Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

  2023cites this paper
• Transforming a Toxic Non-Ionizable Drug into an Efficacious Liposome via Ionizable Prodrug and Remote Loading Strategies against Malignant Breast Tumors.

  2023cites this paper
• Application of Convergent Science and Technology toward Ocular Disease Treatment

  2023influential citation
• New Technological Approaches for Dental Caries Treatment: From Liquid Crystalline Systems to Nanocarriers

  2023cites this paper
• Applications of Nanotechnology in Medical field

  2023cites this paper
• Nanoparticles in Ophthalmology

  2022influential citation
• An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

  2022cites this paper
• Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation

  2022cites this paper
• TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems

  2022cites this paper
• Multifunctional attributes of nanostructured materials, toxicology, safety considerations, and regulations

  2022cites this paper
• Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

  2022cites this paper
• Human SMILE-Derived Stromal Lenticule Scaffold for Regenerative Therapy: Review and Perspectives

  2022cites this paper
• Application of nanotechnology in ophthalmology: Where are we?

  2022cites this paper
• Surface Modification of Lipid-Based Nanoparticles.

  2022cites this paper
• Applications of hybrid nanocrystals in drug delivery

  2022cites this paper
• The utility and risks of therapeutic nanotechnology in the retina

  2021cites this paper
• Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

  2021cites this paper
• Nanopharmaceuticals: Principles and Applications Vol. 2

  2021cites this paper
• Tissue Engineering Meets Nanotechnology: Molecular Mechanism Modulations in Cornea Regeneration

  2021cites this paper
• Application Prospects for Synthetic Nanoparticles in Optogenetic Retinal Prosthetics

  2021cites this paper
• Metal‐HisTag coordination for remote loading of very small quantities of biomacromolecules into PLGA microspheres

  2021cites this paper
• Системы доставки офтальмологических препаратов (обзор)

  2021cites this paper
• CLEAR - Contact lens technologies of the future.

  2021cites this paper
• Nano-pharmacokinetics: interface of physics, chemistry and biology

  2021cites this paper
• Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

  2021cites this paper
• Redox-Responsive Hyaluronic Acid-Based Nanogels for the Topical Delivery of the Visual Chromophore to Retinal Photoreceptors

  2021cites this paper
• Management of Waste Using Nanotechnology

  2021cites this paper
• Aplicaciones de la nanotecnología en el campo de la oftalmología: ¿dónde estamos?

  2020cites this paper
• Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices

  2020cites this paper
• Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases

  2020cites this paper
• Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation.

  2020cites this paper
• Nanocarriers for effective drug delivery

  2020cites this paper
• Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma

  2020cites this paper
• Preparation of Protein–Peptide–Calcium Phosphate Composites for Controlled Protein Release

  2020cites this paper
• Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs

  2020cites this paper
• Zeolites for theranostic applications.

  2020cites this paper
• Microglia Inhibition Delays Retinal Degeneration Due to MerTK Phagocytosis Receptor Deficiency

  2020cites this paper
• Topical Ocular Delivery of Nanocarriers: A Feasible Choice for Glaucoma Management.

  2020cites this paper
• Natural Products and Nanopharmaceuticals

  2020cites this paper
• Nanodiagnostics and Nanotherapeutics for age-related macular degeneration.

  2020cites this paper
• Nanodrugs used in cancer therapy.

  2019cites this paper
• Role of Liposomes-Based Stem Cell for Multimodal Cancer Therapy

  2019cites this paper
• Novel Liposome Aggregate Platform (LAP) system for sustained retention of drugs in the posterior ocular segment following intravitreal injection.

  2019cites this paper
• Transdermal and Intravenous Nano Drug Delivery Systems

  2019cites this paper
• Clinical Aspects and Regulatory Requirements for Nanomedicines

  2019cites this paper
• Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019

  2019cites this paper
• Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection

  2019cites this paper
• Smart Mesoporous Silica Glyconanoparticles for Theranostics

  2018cites this paper
• Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases.

  2018cites this paper
• TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma

  2018cites this paper
• Nanopartikel als Drug-Delivery-Systeme für die Ophthalmologie

  2018cites this paper
• Double Emulsion Mucoadhesive Nanoparticles for Hydrophilic Ocular Drug Delivery

  2018cites this paper
• Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients

  2018influential citation
• Comparative Study of PEGylated and Conventional Liposomes as Carriers for Shikonin

  2018cites this paper
• Delivery of therapeutics for deep‐seated ocular conditions – status quo

  2018influential citation
• Engineering Multifunctional Nanomedicine Platforms for Drug Delivery and Imaging

  2018cites this paper
• Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma.

  2017cites this paper
• Nano-ophthalmology: Applications and considerations.

  2017cites this paper
• Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

  2017cites this paper
• Current advances in the treatment of neovascular age-related macular degeneration

  2017cites this paper
• Effective Retinal Penetration of Lipophilic and Lipid-Conjugated Hydrophilic Agents Delivered by Engineered Liposomes.

  2017cites this paper
• Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy?

  2017cites this paper
• Dorzolamide Loaded Niosomal Vesicles: Comparison of Passive and Remote Loading Methods

  2017cites this paper
• Optimising nanomedicine pharmacokinetics using PBPK modelling

  2017cites this paper
• Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release ocular delivery

  2017cites this paper
• Nanotechnological Interventions for Drug Delivery in Eye Diseases

  2017cites this paper
• Ophthalmic Nanosuspensions: Toxicity and Formulation

  2016cites this paper
• Responsive self-assembled nanostructured lipid systems for drug delivery and diagnostics.

  2016cites this paper
• Nanocrystal for ocular drug delivery: hope or hype

  2016cites this paper
• Preparation and ocular pharmacokinetics of hyaluronan acid-modified mucoadhesive liposomes

  2016cites this paper
• Colloidal drug delivery system: amplify the ocular delivery

  2016cites this paper
• Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration

  2016cites this paper
• Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.

  2016cites this paper
• Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

  2016cites this paper
• FUNDAMENTAL ASPECTS IN THE DEVELOPMENT OF MICROEMULSION SYSTEMS CONTAINING AMPHOTERICIN B FOR OPHTHALMIC USE

  2016cites this paper
• Drug delivery systems for the posterior segment of the eye – in vitro evaluation of light triggered and pH-sensitive liposomes with gold nanoparticles

  2016cites this paper
• Progress of Controlled Drug Delivery Systems in Topical Ophthalmology: Focus on Nano and Micro Drug Carriers

  2016cites this paper